5EA Stock Overview
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Elanco Animal Health Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.17 |
| 52 Week High | US$17.12 |
| 52 Week Low | US$7.49 |
| Beta | 1.5 |
| 1 Month Change | 44.10% |
| 3 Month Change | 1.97% |
| 1 Year Change | -28.37% |
| 3 Year Change | -49.83% |
| 5 Year Change | -35.08% |
| Change since IPO | -60.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5EA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 32.5% | -4.1% | 1.2% |
| 1Y | -28.4% | -27.8% | 14.0% |
Return vs Industry: 5EA underperformed the German Pharmaceuticals industry which returned -24.3% over the past year.
Return vs Market: 5EA underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| 5EA volatility | |
|---|---|
| 5EA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 5EA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 5EA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 9,225 | Jeff Simmons | www.elanco.com |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
Elanco Animal Health Incorporated Fundamentals Summary
| 5EA fundamental statistics | |
|---|---|
| Market cap | €5.75b |
| Earnings (TTM) | €333.57m |
| Revenue (TTM) | €3.96b |
17.2x
P/E Ratio1.5x
P/S RatioIs 5EA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5EA income statement (TTM) | |
|---|---|
| Revenue | US$4.43b |
| Cost of Revenue | US$2.00b |
| Gross Profit | US$2.43b |
| Other Expenses | US$2.06b |
| Earnings | US$373.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 54.89% |
| Net Profit Margin | 8.43% |
| Debt/Equity Ratio | 69.2% |
How did 5EA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 14:36 |
| End of Day Share Price | 2025/05/15 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elanco Animal Health Incorporated is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Ardalan Arfaei | BMO Capital Markets Equity Research |